GCWM
GILD icon

Graham Capital Wealth Management’s Gilead Sciences GILD Stock Holding History

Graham Capital Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20,777
Closed -$1.28M – 84
2022
Q2 		$1.28M Sell
20,777
-59
-0.3% -$3.65K 1.13% 36
2022
Q1 		$1.24M Sell
20,836
-1,256
-6% -$80.3K 1.1% 37
2021
Q4 		$1.58M Buy
+22,092
New +$1.52M 1.29% 30

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Graham Capital Wealth Management's GILD Position: Q3 2022 in Review

Graham Capital Wealth Management sold out of Gilead Sciences (GILD) in Q3 2022, closing a stake of 20,777 shares — an estimated $1.28M sold.

Graham Capital Wealth Management first reported a position in GILD in Q4 2021 and held it in 3 quarters. The position peaked at $1.58M in Q4 2021. 1,602 funds tracked by Wall St. Rank hold GILD as of Q3 2022.

  • Graham Capital Wealth Management reported no remaining Gilead Sciences position as of Q3 2022 after selling out during the quarter.
  • Graham Capital Wealth Management sold 20,777 Gilead Sciences shares in Q3 2022, an estimated $1.28M.
  • Graham Capital Wealth Management first reported a position in Gilead Sciences in Q4 2021 and held it in 3 quarters.
  • Graham Capital Wealth Management's Gilead Sciences position peaked at $1.58M in Q4 2021.
  • 1,602 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.

Based on Graham Capital Wealth Management's 13F filing for Q3 2022, filed 10 Nov 2022.